What if you invested $1000 in MRNA on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 8 years, Moderna, Inc. has delivered an average annual return of 52.4%. The stock peaked in 2020 with a massive +443.3% gain, while investors faced a downturn in 2024 (-63.0%). Overall, the stock finished in the green 3 times out of 8 years.
Avg Return
+52.4%
Win Rate
38%
3W - 5L
Best
+443.3%
2020
Worst
-63.0%
2024
Performance Consistency
About Moderna, Inc.
Visit Website ↗Moderna is a biotechnology company pioneering a new class of medicines made of messenger RNA (mRNA). Its platform enables the development of vaccines and therapeutics for infectious diseases, immuno-oncology, and rare diseases.
Key Business Segments
Infectious Diseases
COVID-19 vaccines, flu vaccines, RSV vaccines.
Oncology
Personalized cancer vaccines.
Key Innovations
- ✓mRNA technology platform
- ✓Spikevax (COVID-19 vaccine)
Historical Milestones
Founded by Flagship Pioneering.
IPO on NASDAQ (largest biotech IPO at the time).
FDA Emergency Use Authorization for COVID-19 vaccine.